DR. J. JAMES FROST
Overview of My Research
Dr. J. James Frost received his M.D. and Ph.D. degrees from Washington University; his Ph.D. degree is in nuclear and radiochemistry. He also obtained an M.B.A. degree from John Hopkins University. Currently, Dr. Frost is President of BioMolecular Imaging and Retired Professor at The Johns Hopkins University School of Medicine, Department of Radiology.
Molecular imaging Specialist
Clinical trials reader
Clinical radiology and nuclear medicine
Consulting for pharma, CROs, diagnostics, and biotech
Dr. J. James Frost's focus in chemistry was nuclear and radiochemistry, which involved instruction in nuclear structure, quantum mechanics, and higher mathematics. Dr. J. James Frost's areas of focus involve fundamental symmetries and broken symmetries that are the basis of many scientific theories and which pervade the natural world.
"This early exposure and training became reanimated when I conceived and wrote a scientific paper in 2018 on symmetry and symmetry-breaking in cancer " ...a belated demonstration of foundational qualities of chemistry.
Then in Jim founded BioMolecular Imaging Consultants where he provides expert advice on anatomic & molecular imaging from entire organ systems to small molecules, peptides & antibodies for use in early clinical and clinical settings, trial design, data analysis, image reading as well as with all FDA liaisons, CROs and academic imaging sites.
Served as the internal clinical imaging expert for a large public biotech company in a FIH clinical trial for a novel cancer imaging radiolabeled peptide
Chaired an advisory board meeting for a large US corporation for post approval rollout and a new CNS probe-specific imaging workstation.
Evaluated U.S. imaging CRO’s for a large international CRO during a multi-month project to select an imaging CRO partner
Developed an imaging strategy, created imaging protocols, and identified preclinical/clinical imaging sites for an antibody cancer therapeutic program of a public biotech corporation
Developed and evaluated post approval strategies and phase IV imaging opportunities for a large pharma CNS diagnostic imaging agent
Provided due diligence guidance to a venture capital company in consideration of funding a preclinical CRO start-up. Identified and interfaced with additional VC’s for syndication funding
Advised a large pharma company in the development of an imaging strategy and protocol to examine CNS side effects of a new drug candidate
Developed a business plan and scientific strategy for a diagnostic cancer imaging start-up company
Developed an imaging strategy and experimental design for a novel organ imaging need of a small cap pharmaceutical company